retatrutide parkinson's disease trial nct Quarterly Drug Pipeline: July 2024 - Prime Therapeutics retatrutide parkinson's disease trial nct

Sulfonylureas Current evidence demonstrates significant heterogeneity in the effects of sulfonylureas on cancer risk

Fatigue and constipation are commonly reported, along with nausea during dose escalation

They are increasingly prescribed by providers because their effect on weight loss surpasses older weight loss pharmacotherapies

Furthermore, it was demonstrated that GLP-1 receptor plays a regulatory role in the hippocampal function and GLP-1 receptor agonists enhanced GABAA signaling through pre-and postsynaptic mechanisms in rats [57], while exendin-4 therapy normalized cognitive dysfunction and improved impaired hippocampal synaptic plasticity in a mice model of diet-induced obesity [58]